Crossmark

Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries

Crossref DOI link: https://doi.org/10.1186/s13054-022-04020-1

Published Online: 2022-05-19

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Goto, Tadahiro

Kudo, Daisuke

Uchimido, Ryo

Hayakawa, Mineji

Yamakawa, Kazuma

Abe, Toshikazu

Shiraishi, Atsushi

Kushimoto, Shigeki
License Information

Text and Data Mining valid from 2022-05-19

Version of Record valid from 2022-05-19
More Information

Article History

Received: 7 March 2022

Accepted: 9 May 2022

First Online: 19 May 2022

Declarations

:

: The three original studies were approved, and the need for informed consent was waived by the institutional review boards at the participating hospitals.

: Not applicable.

: DK, MH, and SK received personal fees from Asahi Kasei Pharma Corporation. TG is the Chief Scientific Officer at TXP Medical Co. Ltd.

Document is current

Any future updates will be listed below